MedTrace Logo

177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

NCT04663997 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2026-03-27

No results posted yet for this study

Summary

177Lu PSMA 617 is a new type of therapy which is designed to deliver high doses of radiation directly to prostate cancer sites in the body. The purpose of this study is to find out whether 177Lu PSMA 617can slow the growth of prostate cancer compared to standard chemotherapy treatment

Conditions

Interventions

DRUG

177Lu-PSMA-617

IA of 7.4GBq (± 10%) IV every 6 weeks; maximum 6 cycles

DRUG

Docetaxel

75mg/m2 IV every 3 weeks maximum 12 cycles

Sponsors & Collaborators

  • Prostate Cancer Canada

    collaborator OTHER

  • Novartis Pharmaceuticals

    collaborator INDUSTRY

  • Canadian Cancer Trials Group

    lead NETWORK

Principal Investigators

  • Kim Chi · BCCA - Vancouver Cancer Centre, BC Canada

  • Francois Benard · BCCA - Vancouver Cancer Centre, BC Canada

  • Fred Saad · CHUM-Centre Hospitalier de l'Universite de Montreal, Canada

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-11
Primary Completion
2025-08-25
Completion
2026-12-31
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04663997 on ClinicalTrials.gov